Interferon Alpha Association with Neuromyelitis Optica

Table 1

Clinical characteristics of patients with neuromyelitis optica (NMO) and multiple sclerosis (MS).

Clinical characteristics	NMO 𝑛=36	MS 𝑛=41	𝑃 value	OR (95%)
Detectable interferon-alpha	9/36	2/41	0.0197	6.5 (1.18–64.96)
Females	25	33	0.2986	0.55 (0.17–1.77)
Positive anti-AQP4 Ab	22	0	<0.0001	NA*
≥3 vertebral segments spinal cord lesion	30	0	<0.0001	NA
Treatment	27	36	0.2358	0.42 (0.01–1.59)
Interferon-beta	6	27	<0.0001	0.10 (0.03–0.34)
Natalizumab	15	9	0.0851	2.54 (0.85–7.82)
Azathioprine	5	0	0.0191	NA
Rituximab	1	0	0.4675	NA
EDSS; median (range)	5 (2–9)	4 (2–9)	0.046	NA

∗NA: Nonapplicable.